CRISM Therapeutics launches retail offer to raise up to £100,000

LONDON - CRISM Therapeutics Corporation (AIM:CRTX) announced Monday a retail offer to raise up to £100,000 through the issuance of new ordinary shares priced at 12 pence per share.

The retail offer, which opened today, is being conducted alongside a separate placing of new shares at the same price. The retail offer is specifically targeted at existing shareholders in the United Kingdom (TADAWUL:4280) and will close on July 2, 2025.

According to the company’s statement, proceeds from both the retail offer and the placing will fund the continued development of ChemoSeed, its treatment candidate for glioblastoma. The funds will specifically support GMP manufacture, sterilization, batch qualification, packaging and distribution of a clinical batch for a Phase 2 registration grade clinical trial.

The company also indicated that the proceeds will cover clinical trial setup costs, with plans to dose the first patients in early 2026.

The retail offer is conditional upon the shares being admitted to trading on the AIM market operated by the London Stock Exchange (LON:LSEG), with admission expected to take place on July 8, 2025. The completion of the retail offer is also contingent upon the completion of the separate placing.

SP Angel Corporate Finance LLP is acting as the retail offer coordinator. Existing retail shareholders can participate by contacting their brokers or wealth managers, provided these intermediaries are onboarded to the BookBuild platform.

CRISM Therapeutics stated in its press release that it values its retail shareholder base and believes it appropriate to provide UK retail shareholders the opportunity to participate in the fundraising.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.